For women between the ages of 40 and 55, metastatic breast cancer is the leading cause of death. Taxotere was developed and is being made available worldwide by Rhone-Poulenc Rorer Inc. , a global pharmaceutical company dedicated to improving human health. This action prohibits cancer cell division, which stops tumor growth and ultimately causes cancer cell death. During the cell cycle, microtubules first assemble and then disassemble. This process allows cancer cells to divide, which causes tumors to grow.
Results are consistent and reproducible across Europe, Japan and the United States.
This regimen is convenient for patients, allowing them to spend more time at home. The range of available dosages will allow healthcare professionals to tailor the treatment to meet individual patient needs. In patients with normal liver function, they include neutropenia, thrombocytopenia, anemia, fluid retention, hypersensitivity, nausea and diarrhea. It is recommended that patients receive a premedication regimen of corticosteroids to prevent or reduce the severity of fluid retention and hypersensitivity. Taxotere may not be appropriate therapy for some patients with liver impairment.